Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy - - BioPharm International

ADVERTISEMENT

Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy


blog comments powered by Disqus


Angie Drakulich, Editorial Director of BioPharm International, talks with Mike Clayman, CEO of Flexion Therapeutics. Based in Woburn, MA, the company works to develop therapeutics for musculoskeletal disorders. In this podcast, Clayman discusses why the company chose to focus on a full range of treatments for one particular disease, osteoarthritis, and how the approach has helped the company fill its biopharmaceutical pipeline and market space. Posted Apr. 2012.

ADVERTISEMENT

ADVERTISEMENT

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Author Guidelines

Click here